IA
CNST

IFP Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

IFP Advisors’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed -$50 – 3171
2020
Q3 		$0 Buy
+2
New +$49 ﹤0.01% 3076

Other funds holding CNST

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

IFP Advisors's CNST Position: Q4 2020 in Review

IFP Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q4 2020, closing a stake of 2 shares — an estimated $50 sold.

IFP Advisors first reported a position in CNST in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 134 funds tracked by Wall St. Rank hold CNST as of Q4 2020.

  • IFP Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • IFP Advisors sold 2 Constellation Pharmaceuticals, Inc. shares in Q4 2020, an estimated $50.
  • IFP Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • IFP Advisors's Constellation Pharmaceuticals, Inc. position peaked at $0 in Q3 2020.
  • 134 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q4 2020.

Based on IFP Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.